It is currently 19 Oct 2017, 17:29

Close

GMAT Club Daily Prep

Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.

Customized
for You

we will pick new questions that match your level based on your Timer History

Track
Your Progress

every week, we’ll send you an estimated GMAT score based on your performance

Practice
Pays

we will pick new questions that match your level based on your Timer History

Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.

Close

Request Expert Reply

Confirm Cancel

Events & Promotions

Events & Promotions in June
Open Detailed Calendar

In clinical trials of new medicines, half of the subjects receive

  new topic post reply Question banks Downloads My Bookmarks Reviews Important topics  
Author Message
TAGS:

Hide Tags

VP
VP
User avatar
D
Status: Long way to go!
Joined: 10 Oct 2016
Posts: 1182

Kudos [?]: 885 [0], given: 54

Location: Viet Nam
GMAT ToolKit User Premium Member CAT Tests
In clinical trials of new medicines, half of the subjects receive [#permalink]

Show Tags

New post 20 Sep 2017, 02:52
00:00
A
B
C
D
E

Difficulty:

  85% (hard)

Question Stats:

48% (01:13) correct 52% (01:40) wrong based on 90 sessions

HideShow timer Statistics

In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated
because __________.

Which one of the following, if true, most appropriately completes the explanation?

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not

(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy volunteers

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo

Source: LSAT
[Reveal] Spoiler: OA

_________________

Actual LSAT CR bank by Broall

How to solve quadratic equations - Factor quadratic equations
Factor table with sign: The useful tool to solve polynomial inequalities
Applying AM-GM inequality into finding extreme/absolute value

New Error Log with Timer

Kudos [?]: 885 [0], given: 54

Intern
Intern
avatar
B
Joined: 23 Feb 2017
Posts: 38

Kudos [?]: 1 [0], given: 8

Re: In clinical trials of new medicines, half of the subjects receive [#permalink]

Show Tags

New post 20 Sep 2017, 03:01
1
This post was
BOOKMARKED
I am with A.. answer choice should pose some concern on the experiment itself if we don't know who is using placebo and who is using medication..

Sent from my XT1575 using GMAT Club Forum mobile app

Kudos [?]: 1 [0], given: 8

Intern
Intern
avatar
B
Joined: 17 Jun 2008
Posts: 9

Kudos [?]: 1 [0], given: 9

GMAT ToolKit User Reviews Badge
Re: In clinical trials of new medicines, half of the subjects receive [#permalink]

Show Tags

New post 20 Sep 2017, 03:14
IMO A

B - As per this choice even the subjects given Placebo will show improvement as do the subjects given drug being tested. Therefore in such cases the experimenters will not clearly find out which subjects are actually being given the drug tested.
C - Subject being healthy volunteers is not relevant to the argument.
D - Duration of the trail is not relevant to the argument.
E - Requirements of the law is not relevant to the argument.

Kudos [?]: 1 [0], given: 9

Manager
Manager
User avatar
S
Joined: 30 Jan 2017
Posts: 73

Kudos [?]: 54 [0], given: 31

Location: India
Schools: ISB '19
GMAT 1: 630 Q47 V29
GPA: 3.9
CAT Tests
Re: In clinical trials of new medicines, half of the subjects receive [#permalink]

Show Tags

New post 12 Oct 2017, 02:49
broall wrote:
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated
because __________.

Which one of the following, if true, most appropriately completes the explanation?

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not

(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy volunteers

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo

Source: LSAT


The intent of using placebo is that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. Now, what if by some means the experimenters are able to differentiate between the two kind of subject (with and without placebo) ? Will the experimenters be frustrated ? Yes. That's the exact situation we are looking for.

Option A says that the experimenters know about the side effects of the drug being tested. Now, if the subjects start showing these exact side-effects, the experimenters will easily identify the subjects to whom the actual drug is administered.

Hence, this situation will frustrate the experimenters and Option A is our answer !!

Kudos [?]: 54 [0], given: 31

Intern
Intern
avatar
B
Joined: 23 Jul 2012
Posts: 10

Kudos [?]: 7 [0], given: 4

Location: United States
Concentration: Entrepreneurship, Strategy
GMAT 1: 690 Q50 V33
GMAT 2: 700 Q50 V34
GRE 1: 1430 Q800 V630
GPA: 3.08
WE: Research (Pharmaceuticals and Biotech)
Re: In clinical trials of new medicines, half of the subjects receive [#permalink]

Show Tags

New post 18 Oct 2017, 18:03
IMO A is the correct answer. Only this suggests that the experimenters will be able to know which group is on which medicine. Hence, the frustration.

Kudos [?]: 7 [0], given: 4

Re: In clinical trials of new medicines, half of the subjects receive   [#permalink] 18 Oct 2017, 18:03
Display posts from previous: Sort by

In clinical trials of new medicines, half of the subjects receive

  new topic post reply Question banks Downloads My Bookmarks Reviews Important topics  


GMAT Club MBA Forum Home| About| Terms and Conditions| GMAT Club Rules| Contact| Sitemap

Powered by phpBB © phpBB Group | Emoji artwork provided by EmojiOne

Kindly note that the GMAT® test is a registered trademark of the Graduate Management Admission Council®, and this site has neither been reviewed nor endorsed by GMAC®.